VSL#3 – the first highly concentrated therapeutic probiotic with multiple bacterial strains and a proven therapeutic efficacy
Luděk Hrdlička Orcid.org 1,2
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7 (11): 1202–1209. doi: 10.1016/j.cgh.2009.07.016.
2. Miele E, Pascarella F, Giannetti E et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104 (2): 437–443. doi: 10.1038/ajg.2008.118.
3. Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind randomized placebo-controlled study. Am J Gastroenterol 2010; 105 (10): 2218–2227. doi: 10.1038/ajg.2010.218.
4. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365 (18): 1713–1725. doi: 10.1056/NEJMra1102942.
5. Gionchetti P, Rizzllo F, Venturi A et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124 (5): 1202–1209.
6. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108–114.
7. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17 (5): 687–696.
8. Wong RK, Yang C, Song GH et al. Melatonin regulation as a possible mechanizm for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci 2015; 60 (1): 186–194. doi: 10.1007/s10620-014-3299-8.
9. Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17 (7): 895–904.
10. Parkes GC, Chatoor D, Emmanuel A. The probiotic VSL#3 increases scbm and reduces symptom severity scores in patients with functional constipation. Gut 2011; 60 (Suppl 1) : A163. doi: 10.1136/gut.2011.239301.345.